Protagonist Therapeutics Inc (PTGX) Institutional Ownership & 13F Filings (Q2 2026)

PTGX ranks #1806 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

PTGX is a top-conviction position for Johnson & Johnson — at 37.6% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in PTGX belongs to BlackRock, Inc., but the position matters far more to Johnson & Johnson, who has 37.6% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

BlackRock has added to its PTGX position for two straight quarters, increasing it by $414.9M to reach $1.3B today.

Marshall Wace, LLP has trimmed its PTGX position for two straight quarters, cutting it by $76.2M while still holding $13.4M.

PTGX is down 0.3% today, but institutions show net buying of $1.6B this quarter — a divergence between today's price move and the underlying institutional flow.

PTGX reported a net loss of $130.1M in its latest fiscal year.

• Not yet profitable — net loss of $130.1M in the latest fiscal year
• Revenue declined 89.4% year over year
• Net income declined year over year, from $275.2M to -$130.1M
• Generated $57.7M in positive operating cash flow
• Current ratio of 12.71x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.09x equity — within a conventional range